Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.

Blood - 8 Apr 2010

Driscoll James J, Pelluru Dheeraj, Lefkimmiatis Konstantinos, Fulciniti Mariateresa, Prabhala Rao H, Greipp Philip R, Barlogie Bart, Tai Yu-Tzu, Anderson Kenneth C, Shaughnessy John D, Annunziata Christina M, Munshi Nikhil C

Abstract excerpt

Multiple myeloma (MM) is a plasma cell neoplasm that proceeds through a premalignant state of monoclonal gammopathy of unknown significance; however, the molecular events responsible for myelomagenesis remain uncharacterized. To identify cellular pathways deregulated in MM, we addressed that sumo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma
Share to Plasma Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Small Ubiquitin-Related Modifier Proteins

Share to Stem Cell Transplantation

Share to Stromal Cells

Share to SUMO-1 Protein

Share to Ubiquitin-Conjugating Enzyme UBC9

Share to Ubiquitin-Conjugating Enzymes

Source

Open in PubMed Open full text

Identifiers

PMID: 19965618
DOI: 10.1182/blood-2009-03-211045
PMCID: PMC2854429

Genes

PIAS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19965618-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.PMID 19965618Read ↗

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myelomaSemantic proximity Read ↗

SUMOylation inhibition enhances dexamethasone sensitivity in multiple myelomaSemantic proximity Read ↗

SUMOylation Inhibition Enhances Dexamethasone Sensitivity in Multiple MyelomaSemantic proximity Read ↗

Epigenetic Aberrations in Multiple MyelomaSemantic proximity Read ↗

The biological significance of histone modifiers in multiple myeloma: clinical applicationsSemantic proximity Read ↗

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomideSemantic proximity Read ↗

High expression of UBE2T predicts poor prognosis and survival in multiple myelomaSemantic proximity Read ↗

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cellsSemantic proximity Read ↗

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functionsSemantic proximity Read ↗

Post-Translational Modifications in Multiple Myeloma: Mechanisms of Drug Resistance and Therapeutic OpportunitiesSemantic proximity Read ↗

Serum proteomic profiling reveals MTA2 and AGO2 as novel prognostic biomarkers associated with disease activity and adverse outcomes in multiple myelomaSemantic proximity Read ↗

NSD2-epigenomic reprogramming and maintenance of plasma cell phenotype in t(4;14) myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.